Biotechnology

Vaccinex

Vaccinex to Present New Clinical Data on Pepinemab at ASCO Annual Meeting

Vaccinex to Present New Mechanism of Immune Therapy Enhancement by Pepinemab at AACR Annual Meeting

Vaccinex released FY2024 Q4 earnings on April 15, 2025 (EST) with actual revenue of USD 213 K and EPS of USD -1.0466

Vaccinex released FY2024 Annual Earnings on April 15 (EST), actual revenue USD 601K, actual EPS USD -8.8777

Vaccinex released FY2024 Cumulative Q3 Earnings on November 14, 2024 (EST), with Revenue of 388,000 USD and EPS of -8.8661

Vaccinex released FY2024 Q3 earnings on November 14 (EST), with actual revenue of 52 K USD and EPS of -2.8279 USD

Vaccinex released FY2023 Q4 earnings on April 2, 2024 (EST) with actual revenue of USD 0 and EPS of USD -3.2932

Vaccinex released FY2023 Cumulative 3Q Earnings on November 13 (EST), with Revenue of 570K USD and EPS of -60.6754

Vaccinex released FY2020 Q3 earnings on November 13, 2020 (EST) with actual revenue of 625,000 USD and EPS of -91.5747

SEVEN HILLS RLTY TR COM USD0.001 (S/R 04/12/2025)

SMX Security Matters

Polyrizon

Picard Medical

Synchronoss Tech

PharmaCyte Biotech

Q/C Tech

Rich Sparkle

Hoyne Bancorp

Tradr 2X Long ASTS Daily ETF

ADMA生物制药

Kiniksa Pharmaceuticals

Stoke Therapeutics

Rigel制药

OpGen

福泰制药

再生元制药

阿里拉姆制药

Argenx

百济神州

Style Score

Growth Score

Revenue YoY

Net Profit YoY

Value Score

P/B Ratio

Dividend Ratio

Size Score

Market Cap Score

Market Cap

Revenue Score

Revenue

Multi Score

Profit Score

Profit Margin

Gross Margin

Total Assets YoY

Net Assets YoY

Cash Score

Cash Flow Margin

OCF YoY

Operating Score

Turnover

Debt Score

Gearing Ratio

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap